Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.
Immutep’s combination of its LAG-3 protein/MHC (major histocompatibility complex) Class II agonist eftilagimod alfa and Merck & Co.’s immuno-oncology blockbuster Keytruda (pembrolizumab) has shown impressive median overall survival (OS) of 17.6 months in Cohort B (31 evaluable patients) of the TACTI-003 (KEYNOTE-C34) Phase IIb trial.
The trial is evaluating the combo as a first-line therapy in recurrent/metastatic head and neck squamous cell carcinoma patients with...
The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.
The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger
